<DOC>
	<DOCNO>NCT01937182</DOCNO>
	<brief_summary>We wish conduct prospective , randomize , double blind , placebo control multi center study combine neuroprotective antithrombotic effect SSRI treatment stroke . Hypotheses : SSRI treatment commence acute phase stroke ( day 0-7 ) protect new thromboembolic event lead good rehabilitation . 600 stroke patient randomize 1:1 ratio . The treatment follow period 6 month . During 6 month 2 clinical follow visit , one telephone control one visit evaluate compliance regard medication .</brief_summary>
	<brief_title>The Efficacy Citalopram Treatment Acute Stroke</brief_title>
	<detailed_description>Design TALOS investigator-initiated , national multicenter randomized- placebo-controlled , double blind trial test citalopram acute ischemic stroke . Randomization Eligible patient randomize 1:1 treatment either citalopram placebo . Treatment allocation double-blinded base computer-generated algorithm via dedicate website . Patients whose treatment stop within 31 day inclusion replace . Intervention follow-up Patients randomize citalopram receive oral treatment 20 mg tablet ( 10 mg age â‰¥65 and/or reduce liver function ) 6 month telephone contact 2 week 3 month follow-up visit 1 6 month . If patient develop depression dosage initially double , follow additional control evaluate effect , necessary , shift open-label antidepressant treatment . After 6 month , treatment either stop switch open-label antidepressant discretion investigator . Substudy 120 patient begin treatment within 12 hour treatment recombinant tissue plasminogen activator . These patient receive standard acute magnetic resonance imaging ( MRI ) additional perfusion angio sequence . The 24-hour control scan do use MRI instead conventional CT. Data monitoring When 300 patient include trial , interim analysis perform . The unblinded result analysis review independent data monitoring committee .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>First ever ischemic stroke Age 18 year Hemorrhagic stroke Dementia neurodegenerative disease Antidepressant medical treatment within 6 month admission Acute need antidepressant treatment Drug abuse condition may indicate noncompliant behavior Liver failure ( increase liver enzyme level 2 time upper limit ) Renal failure ( eGFR 30 ml/min per 1.73m2 ) Hyponatremia ( Spotassium 130 mmol/l ) Actively bleed ulcer Fatal stroke severe comorbidity markedly decrease expect life span Prolonged correct QTinterval ( QTc 480 m ) Ongoing treatment drug know prolong QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Stroke</keyword>
	<keyword>SSRI ( Selective Serotonin Reuptake Inhibitors )</keyword>
	<keyword>Serotonin</keyword>
	<keyword>5-HT ( 5-Hydroxytryptamine )</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>MRI ( Magnetic Resonance Imaging )</keyword>
	<keyword>Platelet</keyword>
	<keyword>CT ( computerized tomography )</keyword>
	<keyword>Post Stroke Depression</keyword>
</DOC>